In Asia, activating mutations in exons 18–21 of the EGFR tyrosine kinase domain occur in around 50% of NSCLC cases, resulting in the constant activation of signaling pathways that promote cell proliferation and inhibit apoptosis, independent of extracellular ligands [31]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.